SeroCovid<19: Covid-19 Seroconversion in Tertiary Pediatric Patients
SeroCovid<19: A Prospective Covid-19 Seroconversion Study in a Tertiary Pediatric Patient Cohort
1 other identifier
observational
362
1 country
1
Brief Summary
Children are relatively spared from the direct clinical impact of COVID-19. Pediatric patients with regular follow-up at tertiary pediatric centres and presenting one or more chronic conditions might be at increased risk for severe COVID-19. With a prospective seroprevalence study, we aim to study COVID-19 incidence, disease course and risk factors associated with SARS-CoV-2 infection in this specific context.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 29, 2020
CompletedFirst Submitted
Initial submission to the registry
November 3, 2020
CompletedFirst Posted
Study publicly available on registry
November 4, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2021
CompletedJuly 1, 2022
November 1, 2020
1 year
November 3, 2020
June 27, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Seroconversion rate of children with chronic conditions followed in a tertiary centre
Prospective follow-up of the COVID-19 seroconversion rate (serum IgG) of children with chronic conditions followed in a tertiary centre
12-18 months
Secondary Outcomes (2)
Epidemiological and social determinants of SARS-CoV-2 infection risk in children with chronic conditions
12-18 months
Clinical manifestations of COVID-19 in children with chronic conditions
12-18 months
Interventions
Periodic assessment of the serology status (SARS-CoV-2 specific IgG) with a 3 to 6 month interval
Eligibility Criteria
* children \<18 years of age * a clearly defined chronic condition requiring follow-up at the tertiary pediatric hospital of the Ghent University Hospital
You may qualify if:
- children \<18 years of age
- a clearly defined chronic condition requiring follow-up at the tertiary pediatric hospital of the Ghent University Hospital
- routine blood sampling planned per 3 to 6 months
You may not qualify if:
- no clear diagnosis or reason for follow-up at the Ghent University Hospital
- no routine blood sampling planned
- unable to understand or provide informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University Hospital, Ghentlead
- University Ghentcollaborator
Study Sites (1)
Ghent University Hospital
Ghent, 9000, Belgium
Biospecimen
serum samples
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Filomeen Haerynck, MD, PhD
University Hospital, Ghent
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 18 Months
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 3, 2020
First Posted
November 4, 2020
Study Start
October 29, 2020
Primary Completion
November 1, 2021
Study Completion
November 1, 2021
Last Updated
July 1, 2022
Record last verified: 2020-11